TAAR1 and Sepsis: A previous meta-analysis of 19 studies involving 1354 adult patients suggested that Tα1 might benefit patients with sepsis (Liu F. et al., 2016), However, the subsequent TESTS trial, the largest multicenter, double-blind RCT to date with 1106 patients with sepsis, found no mortality reduction or clinical improvement with Tα1, though elderly and diabetic subgroups showed potential effects (Wu et al., 2025), While the TESTS findings may influence practice, a comprehensive analysis of all available data is needed to establish definitive clinical guidance.